Recent Articles in Deals & Financings

Hangzhou Zylox-Tonbridge, a peripheral and neurovascular interventional device company, entered a $15 million deal to distribute and manufacture the entire device line of California’s Avinger in China. Avinger offers intra-vascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease. Zylox-Tonbridge, which will have Greater China rights to the products, will buy $7.5 million of Avinger stock upfront and the rest after technology transfer. Avinger will also have distribution rights in the US and Germany for Zylox-Tonbridge’s peripheral vascular products. More details....

Share this with colleagues:  

Shanghai Haihe Biopharma out-licensed Japan and Southeast Asia rights for its lead drug, gumarontinib, an approved therapy for non-small cell lung cancer, to Taiho Pharma of Tokyo. In March 2023, gumarontinib was approved in China to treat non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping mutations. Haihe has already applied for Japanese approval of the drug. Taiho will have rights to develop, manufacture and commercialize gumarontinib in its areas. Haihe will receive an upfront payment, and it will be eligible for milestones and royalties based on sales revenues. More details....

Share this with colleagues:  

Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Mabwell will receive $10 million upfront. 9MW3011 is designed to lower the serum level of iron, regulating iron homeostasis in vivo. It is expected to treat patients with rare diseases including β-thalassemia, polycythemia vera and other conditions related to iron homeostasis. 9MW3011, which has been approved to start trials in China and the US, was developed in Mabwell’s San Diego Innovation R&D Center. More details....

Share this with colleagues:  

Zhuhai’s Biotheus formed a multi-year collaboration with Bitterroot Bio of Palo Alto to discover novel approaches that modulate the immune system and regulate inflammation, with the goal of addressing atherosclerosis and other potentially fatal cardiovascular conditions. Biotheus will design novel monoclonal and multi-specific antibodies using its proprietary platforms. Bitterroot will add its expertise in cardiovascular medicine and biology to the partnership. Bitterroot is a cardio-immunology company that focuses on the impact of the immune system on cardiovascular health. More details....

Share this with colleagues: